Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klebsiella pneumoniae | 5 | 2020 | 72 | 0.970 |
Why?
|
| beta-Lactamases | 5 | 2020 | 195 | 0.740 |
Why?
|
| Tuberculosis, Pulmonary | 8 | 2009 | 252 | 0.670 |
Why?
|
| Bacterial Proteins | 6 | 2020 | 876 | 0.660 |
Why?
|
| Guinea Pigs | 13 | 2009 | 169 | 0.600 |
Why?
|
| Anti-Bacterial Agents | 12 | 2024 | 2391 | 0.570 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2024 | 793 | 0.560 |
Why?
|
| Candidemia | 4 | 2023 | 40 | 0.510 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 669 | 0.500 |
Why?
|
| Klebsiella Infections | 4 | 2017 | 51 | 0.470 |
Why?
|
| BCG Vaccine | 6 | 2007 | 115 | 0.470 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 100 | 0.440 |
Why?
|
| beta-Lactam Resistance | 1 | 2013 | 47 | 0.440 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2018 | 359 | 0.430 |
Why?
|
| Cephalosporins | 3 | 2024 | 137 | 0.390 |
Why?
|
| Antimicrobial Stewardship | 2 | 2023 | 84 | 0.350 |
Why?
|
| Candida | 4 | 2023 | 75 | 0.350 |
Why?
|
| Cross Infection | 4 | 2014 | 331 | 0.350 |
Why?
|
| Minocycline | 2 | 2022 | 36 | 0.340 |
Why?
|
| Mycobacterium bovis | 2 | 2007 | 35 | 0.310 |
Why?
|
| Antigens, CD | 2 | 2007 | 421 | 0.300 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 266 | 0.290 |
Why?
|
| Leukocytes | 3 | 2007 | 204 | 0.280 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2007 | 460 | 0.280 |
Why?
|
| Drug Utilization | 3 | 2020 | 157 | 0.270 |
Why?
|
| Hospitals, University | 4 | 2014 | 95 | 0.270 |
Why?
|
| Antifungal Agents | 5 | 2023 | 293 | 0.250 |
Why?
|
| Carbapenems | 2 | 2015 | 36 | 0.220 |
Why?
|
| Vaccination | 3 | 2009 | 946 | 0.220 |
Why?
|
| Eosinophils | 1 | 2004 | 121 | 0.210 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 93 | 0.210 |
Why?
|
| Tuberculosis Vaccines | 3 | 2009 | 16 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1021 | 0.200 |
Why?
|
| Lung | 4 | 2009 | 1483 | 0.190 |
Why?
|
| Communicable Diseases | 1 | 2023 | 163 | 0.190 |
Why?
|
| Macrophages, Peritoneal | 3 | 2006 | 38 | 0.180 |
Why?
|
| Doxycycline | 2 | 2022 | 117 | 0.180 |
Why?
|
| Feces | 2 | 2015 | 711 | 0.180 |
Why?
|
| Ceftazidime | 1 | 2020 | 41 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 130 | 0.170 |
Why?
|
| Clostridium Infections | 2 | 2014 | 230 | 0.170 |
Why?
|
| Urine | 1 | 2020 | 88 | 0.170 |
Why?
|
| Ceftriaxone | 1 | 2018 | 68 | 0.150 |
Why?
|
| Peritonitis | 1 | 2018 | 76 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 169 | 0.150 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 1 | 0.150 |
Why?
|
| Bacteremia | 3 | 2017 | 405 | 0.150 |
Why?
|
| Texas | 8 | 2021 | 3513 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2015 | 118 | 0.140 |
Why?
|
| Immunization, Secondary | 2 | 2009 | 106 | 0.140 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 55 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 490 | 0.140 |
Why?
|
| Bacteria | 2 | 2018 | 483 | 0.140 |
Why?
|
| Spleen | 3 | 2007 | 287 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1676 | 0.130 |
Why?
|
| Echinocandins | 4 | 2023 | 44 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 163 | 0.130 |
Why?
|
| Health Personnel | 1 | 2021 | 500 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 289 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 516 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2018 | 304 | 0.120 |
Why?
|
| Humans | 31 | 2024 | 122300 | 0.120 |
Why?
|
| Fluconazole | 2 | 2012 | 47 | 0.120 |
Why?
|
| Meningitis | 1 | 2015 | 99 | 0.120 |
Why?
|
| Gram-Positive Bacteria | 1 | 2014 | 46 | 0.120 |
Why?
|
| Length of Stay | 3 | 2015 | 1270 | 0.120 |
Why?
|
| Candida glabrata | 1 | 2014 | 18 | 0.120 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 74 | 0.110 |
Why?
|
| Candidiasis, Invasive | 1 | 2014 | 19 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2015 | 176 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2013 | 49 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2014 | 134 | 0.110 |
Why?
|
| Lipopeptides | 3 | 2023 | 33 | 0.110 |
Why?
|
| Rifamycins | 1 | 2013 | 21 | 0.110 |
Why?
|
| Peptidomimetics | 1 | 2013 | 12 | 0.110 |
Why?
|
| Candidiasis | 1 | 2014 | 129 | 0.110 |
Why?
|
| Biological Therapy | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 67 | 0.100 |
Why?
|
| Macrophage Activation | 3 | 2006 | 62 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 999 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2013 | 459 | 0.090 |
Why?
|
| Intensive Care Units | 3 | 2023 | 475 | 0.090 |
Why?
|
| Animals | 13 | 2009 | 33865 | 0.090 |
Why?
|
| Aged | 10 | 2018 | 18756 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 135 | 0.080 |
Why?
|
| Cross Reactions | 2 | 2007 | 192 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 1403 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 2701 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 119 | 0.080 |
Why?
|
| Middle Aged | 11 | 2018 | 25564 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2012 | 0.080 |
Why?
|
| Tuberculosis, Pleural | 2 | 2005 | 10 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2006 | 256 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 635 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2007 | 158 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2015 | 5971 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6288 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 236 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 679 | 0.070 |
Why?
|
| Physicians | 1 | 2012 | 582 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 43 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2005 | 33 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 810 | 0.060 |
Why?
|
| Granuloma | 1 | 2005 | 69 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2005 | 116 | 0.060 |
Why?
|
| Phenotype | 1 | 2013 | 4218 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2003 | 135 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 512 | 0.050 |
Why?
|
| Female | 12 | 2018 | 64911 | 0.050 |
Why?
|
| Male | 11 | 2018 | 59545 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 131 | 0.050 |
Why?
|
| Cytokines | 2 | 2005 | 1286 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 1106 | 0.050 |
Why?
|
| Adult | 6 | 2023 | 28725 | 0.050 |
Why?
|
| Vancomycin | 2 | 2014 | 217 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 298 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2022 | 142 | 0.050 |
Why?
|
| Tuberculosis | 2 | 2005 | 570 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 2371 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 459 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 23 | 0.050 |
Why?
|
| Azabicyclo Compounds | 1 | 2020 | 16 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 39 | 0.050 |
Why?
|
| Mutation | 1 | 2014 | 5782 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 54 | 0.040 |
Why?
|
| Catholicism | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hospitals, Religious | 1 | 2020 | 5 | 0.040 |
Why?
|
| Base Sequence | 1 | 2005 | 3118 | 0.040 |
Why?
|
| Rabbits | 3 | 2006 | 717 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 9863 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1593 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 261 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3231 | 0.040 |
Why?
|
| Phylogeny | 2 | 2017 | 684 | 0.040 |
Why?
|
| Salmonella enterica | 1 | 1998 | 9 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 12016 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1998 | 107 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 3887 | 0.040 |
Why?
|
| DNA, Bacterial | 2 | 2015 | 481 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 113 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2009 | 312 | 0.030 |
Why?
|
| Virulence | 2 | 2007 | 259 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 471 | 0.030 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 2 | 2009 | 376 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 300 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 29 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 2015 | 18 | 0.030 |
Why?
|
| Louisiana | 1 | 2015 | 134 | 0.030 |
Why?
|
| Nanospheres | 1 | 2014 | 6 | 0.030 |
Why?
|
| Enterotoxins | 1 | 2015 | 83 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 119 | 0.030 |
Why?
|
| Enterococcus | 1 | 2014 | 33 | 0.030 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 25 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 88 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 105 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2005 | 2832 | 0.030 |
Why?
|
| Metronidazole | 1 | 2014 | 155 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 93 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 148 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 46 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 335 | 0.030 |
Why?
|
| United States | 3 | 2018 | 10467 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2013 | 103 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 193 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 232 | 0.030 |
Why?
|
| Phospholipids | 1 | 2013 | 107 | 0.030 |
Why?
|
| Biofilms | 1 | 2013 | 93 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 220 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 739 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 382 | 0.020 |
Why?
|
| APACHE | 1 | 2011 | 52 | 0.020 |
Why?
|
| Species Specificity | 2 | 2005 | 552 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 208 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 8800 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 1316 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1412 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 728 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 356 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 148 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1146 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2009 | 263 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 710 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2813 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2793 | 0.020 |
Why?
|
| Tuberculin | 1 | 2007 | 12 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2007 | 18 | 0.020 |
Why?
|
| Aerosols | 1 | 2007 | 66 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 772 | 0.020 |
Why?
|
| Gene Expression | 2 | 2004 | 1591 | 0.020 |
Why?
|
| Ruminants | 1 | 2005 | 2 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1468 | 0.020 |
Why?
|
| Nitrites | 1 | 2006 | 45 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 79 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1727 | 0.020 |
Why?
|
| Horses | 1 | 2005 | 89 | 0.020 |
Why?
|
| Fishes | 1 | 2005 | 41 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 55 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 113 | 0.020 |
Why?
|
| Primates | 1 | 2005 | 80 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 4643 | 0.020 |
Why?
|
| Sheep | 1 | 2005 | 211 | 0.020 |
Why?
|
| Chickens | 1 | 2005 | 637 | 0.020 |
Why?
|
| Polyproteins | 1 | 2004 | 8 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 4479 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 151 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 54 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 2005 | 173 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 129 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2005 | 164 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 559 | 0.010 |
Why?
|
| Pleural Cavity | 1 | 2004 | 6 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 466 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2004 | 238 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 127 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 344 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 3613 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 6170 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1301 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 793 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1158 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 872 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2006 | 736 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2785 | 0.010 |
Why?
|
| Cosmids | 1 | 1998 | 48 | 0.010 |
Why?
|
| Siderophores | 1 | 1998 | 10 | 0.010 |
Why?
|
| Salmonella | 1 | 1998 | 28 | 0.010 |
Why?
|
| Operon | 1 | 1998 | 52 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1998 | 189 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 17613 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 145 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 208 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 18979 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 658 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 900 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 623 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 446 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 4382 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 4307 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 15856 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 981 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 1759 | 0.010 |
Why?
|